Brynn Levy Elected President of the ACMG Foundation for Genetic and Genomic Medicine

Levy succeeds Nancy J. Mendelsohn, MD, FACMG, who will now serve as past president.

Mar. 13, 2026 at 3:51pm

Got story updates? Submit your updates here. ›

Brynn Levy, MSc (Med), PhD, FACMG, has been elected president of the American College of Medical Genetics and Genomics (ACMG) Foundation for Genetic and Genomic Medicine. Levy is a professor of pathology and cell biology at the Columbia University Irving Medical Center, where he serves as medical director of the Cytogenetics Laboratory and co-director of the Laboratory for Personalized Genomic Medicine. Harry Ostrer, MD, FACMG, has been elected president-elect of the ACMG Foundation.

Why it matters

As genomic medicine becomes a foundational pillar of modern healthcare, the demand for expert clinical and laboratory geneticists has reached an all-time high. The ACMG Foundation is at the forefront of establishing the evidence-based standards necessary for the seamless adoption of these advanced diagnostic technologies.

The details

Levy has worked with organizations including the ACMG, the College of American Pathologists, the Cancer Genomics Consortium, and the International Society for Prenatal Diagnosis to establish national and international standards and guidelines for integrating new technologies into clinical practice. Ostrer has conducted research into the genetic basis of common and rare disorders and has advocated for policies addressing genetic discrimination and informed consent in genetic testing.

  • Brynn Levy was elected president of the ACMG Foundation on March 13, 2026.
  • Nancy J. Mendelsohn, MD, FACMG, will now serve as past president of the ACMG Foundation.

The players

Brynn Levy

A professor of pathology and cell biology at the Columbia University Irving Medical Center, where he serves as medical director of the Cytogenetics Laboratory and co-director of the Laboratory for Personalized Genomic Medicine.

Nancy J. Mendelsohn

The outgoing president of the ACMG Foundation, who will now serve as past president.

Harry Ostrer

A professor of pathology and pediatrics at the Albert Einstein College of Medicine, who has been elected president-elect of the ACMG Foundation.

Melissa Forburger

The interim chief executive officer of the ACMG and the ACMG Foundation.

ACMG Foundation

The organization that works to advance ACMG educational and public health programs through philanthropic support.

Got photos? Submit your photos here. ›

What they’re saying

“As genomic medicine becomes a foundational pillar of modern healthcare, the demand for expert clinical and laboratory geneticists has reached an all-time high. Alongside the rollout of advanced diagnostic tools, we face a vital responsibility to educate the broader healthcare community. The ACMG is at the forefront of this effort, establishing the evidence-based standards necessary for the seamless adoption of these technologies.”

— Brynn Levy, President, ACMG Foundation (clpmag.com)

“My vision is to transform the Foundation into a premier philanthropic engine that fuels our most critical priorities: cultivating a robust medical genetics workforce, developing the evidence-based standards that define the practice of genomic medicine, and honoring the stars of our medical genetics community.”

— Harry Ostrer, President-Elect, ACMG Foundation (clpmag.com)

“I have worked closely with both of these clinicians and believe they will lead the Foundation with great intellect, energy, and clarity.”

— Nancy J. Mendelsohn, Outgoing President, ACMG Foundation (clpmag.com)

“Their combined vision and dedication will strengthen the Foundation's philanthropic impact and ensure continued advancement of genetic and genomic medicine in service of patients and families.”

— Melissa Forburger, Interim CEO, ACMG and ACMG Foundation (clpmag.com)

The takeaway

The election of Brynn Levy and Harry Ostrer to lead the ACMG Foundation comes at a critical time as genomic medicine becomes increasingly central to modern healthcare. Their expertise and commitment to advancing the field of medical genetics will be crucial in establishing the standards and workforce needed to ensure the seamless integration of these transformative technologies.